Verrica Pharmaceuticals: A Year of Transformation
The fourth quarter and year-end 2025 corporate update conference call hosted by Verrica Pharmaceuticals provided a comprehensive overview of the company's achievements in commercial, clinical, and financial initiatives. Jayson Rieger, President and CEO, highlighted that 2025 will be remembered as the year Verrica fundamentally transformed its business, setting a solid foundation for the future and supporting long-term value creation for shareholders.
Verrica started 2025 by stabilizing its commercial organization, more than doubling revenue from the core YCANTH business for molluscum while dramatically cutting costs from the previous year. This was achieved through the implementation of a more optimized commercial strategy with the goal of establishing YCANTH as a new standard of care for the treatment of molluscum contagiosum.
As a result, Verrica was able to grow YCANTH revenue by over 130% compared to 2024, while reducing selling general administrative expenses by over 40% from the same period. These results reflect the hard work and dedication of the team, disciplined cost management, and progress in building solid relationships with physicians, payers, and distribution partners.
Additionally, Verrica made important progress in its pipeline, advancing both common warts and basal cell carcinoma programs. The company launched a global phase 3 program study for YCANTH in common warts with Japanese development partner Torii Pharmaceutical, receiving $18 million of milestone payments in the third quarter of 2025.
Verrica also dosed the first patient in the common warts program in December and looks forward to initiating the second phase 3 study in the U.S. and Japan with Torii over the coming months. Furthermore, the company believes its oncolytic peptide asset, VP315, represents one of the most promising opportunities in dermatology and has substantially reduced the cost and time of a phase three program in basal cell carcinoma by aligning with the FDA on a streamlined design of study last year.
These advanced programs could represent significant value drivers for Verrica, with each offering substantial potential. The company's transformation in 2025 sets a solid foundation for future growth and long-term value creation for its shareholders.
